Aquestive Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$3.82

−1.55%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $3.88
Volume: 3.3M
Day's high: —
Day's low: —

In brief

Aquestive Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $479M.
Its shares closed at $3.80 on 4 Nov 2026, down 37.5% over the past year.
From India you can buy AQST in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Aquestive Therapeutics, Inc. (AQST) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole AQST share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade AQST options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −17.6% (SPY −1.6%, XLV +13.5%). 3 months: +1.2% (SPY −0.4%, XLV +15.5%). 1 year: −37.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AQST, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $3.80 was 17.3% below its 50-day average ($4.60) and 9.8% below its 200-day average ($4.21). It has closed below the 200-day for 5 sessions, since 29 Oct 2026. The 50-day average crossed above the 200-day on 21 Sep 2026, 32 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
13.9 days to cover short interest
27.6M shares were sold short at the 15 Oct 2026 settlement, 22.0% of the 125.5M shares outstanding; covering them would take 13.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
22% of the way up its 52-week range
Closed at $3.80 on 4 Nov 2026: 44.5% below the 52-week high of $6.85 (6 Nov 2025) and 29.7% above the low of $2.93 (30 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.6× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 3.3M shares was 1.6× the average of the 30 sessions before it (2.1M), as the price fell 2.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−17.6%

6 months−10.2%

1 year−37.5%

5 years−37.1%

Newswire

About

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Website

Notable moves

February 2, 2026
+38.98%
January 9, 2026
−37.04%
December 21, 2021
−29.26%

Aquestive Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$3.82

−1.55%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $3.88
Volume: 3.3M
Day's high: —
Day's low: —

In brief

Aquestive Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $479M.
Its shares closed at $3.80 on 4 Nov 2026, down 37.5% over the past year.
From India you can buy AQST in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Aquestive Therapeutics, Inc. (AQST) shares from India?

Do I need the price of a whole AQST share to invest?

How much can I invest in US stocks in a year?

Can I trade AQST options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −17.6% (SPY −1.6%, XLV +13.5%). 3 months: +1.2% (SPY −0.4%, XLV +15.5%). 1 year: −37.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AQST, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $3.80 was 17.3% below its 50-day average ($4.60) and 9.8% below its 200-day average ($4.21). It has closed below the 200-day for 5 sessions, since 29 Oct 2026. The 50-day average crossed above the 200-day on 21 Sep 2026, 32 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
13.9 days to cover short interest
27.6M shares were sold short at the 15 Oct 2026 settlement, 22.0% of the 125.5M shares outstanding; covering them would take 13.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
22% of the way up its 52-week range
Closed at $3.80 on 4 Nov 2026: 44.5% below the 52-week high of $6.85 (6 Nov 2025) and 29.7% above the low of $2.93 (30 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.6× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 3.3M shares was 1.6× the average of the 30 sessions before it (2.1M), as the price fell 2.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−17.6%

6 months−10.2%

1 year−37.5%

5 years−37.1%

Newswire

About

Website

Notable moves

February 2, 2026
+38.98%
January 9, 2026
−37.04%
December 21, 2021
−29.26%

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

13.9 days to cover short interest

22% of the way up its 52-week range

Volume 1.6× its 30-session average on 4 Nov 2026

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

13.9 days to cover short interest

22% of the way up its 52-week range

Volume 1.6× its 30-session average on 4 Nov 2026